NASDAQ · PHARMACEUTICAL PREPARATIONS
Journey Medical Corp. DERM
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$61.2M
▲ 11.1% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-44.0%
Net margin · FY25
-18.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 61.2M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 19 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-44.0%
Return on equity, FY2025
ROE
Operating margin-13.3%
Net margin-18.7%
Return on assets-13.1%
Each USD of equity lost 44 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+6.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−4.8%
+6.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 94.6M
total assets, end of FY2025
Total assetsUSD 94.6M
EquityUSD 31.9M
CashUSD 24.1M
Gross debtUSD 25.3M
Net debtUSD 1.2M
Current ratio1.79×
Net debt stands at 4% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
·
·
·
·
−0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−44.0
−72.6
−20.6
−100.4
−168.1
51.3
Shares out B
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed